EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment

pharmanewsdaily- October 28, 2018 0

The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic arthritis treatment, Cosentyx (secukinumab). This update introduces ... Read More

US biopharma company Endocyte to be acquired by Novartis for $2.1bn

pallavi123- October 21, 2018 0

Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 ... Read More

Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition

pharmanewsdaily- October 21, 2018 0

Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More

Aurobindo Pharma to acquire Sandoz US dermatology and oral solids divisions for $1bn

pallavi123- September 9, 2018 0

Aurobindo Pharma, a prominent Indian pharmaceutical company, has agreed to a significant acquisition from Sandoz US, a division of the Swiss pharmaceutical giant Novartis. The ... Read More

Sandoz US to divest dermatology and oral solids businesses to Aurobindo Pharma for $1bn

pharmanewsdaily- September 8, 2018 0

In a strategic move within the pharmaceutical industry, Sandoz US, a subsidiary of the Swiss-based Novartis, has announced the sale of its dermatology and oral ... Read More

Avara Pharmaceutical expands into Canadian market with acquisition of sterile manufacturing facility

pharmanewsdaily- September 8, 2018 0

Avara Pharmaceutical Services, a prominent US-based contract development and manufacturing organization (CDMO), has successfully completed the acquisition of a sterile manufacturing facility for injectable medicines ... Read More

EC approves Novartis’ skin cancer therapy combo Tafinlar and Mekinist for melanoma

pharmanewsdaily- September 1, 2018 0

In a significant development for melanoma treatment, the European Commission (EC) has granted Novartis approval for its combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib). ... Read More

Novartis reveals positive results from Entresto Phase 4 TRANSITION study for heart failure patients

pharmanewsdaily- August 26, 2018 0

Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in ... Read More

Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas

pharmanewsdaily- July 29, 2018 0

In a significant advancement for biopharmaceuticals, Novartis' division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. ... Read More

Novartis secures global rights to atopic dermatitis drug MOR106

pharmanewsdaily- July 21, 2018 0

In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive ... Read More